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 Familial hypercholesterolemia (FH) is an autosomal 
dominant disorder characterized by elevated plasma LDL 
cholesterol, tendon xanthomas, and premature coronary 
heart disease. FH is mostly caused by mutations within the 
low density lipoprotein receptor (LDLR; MIM# 143890) 
gene, or in its ligand apoB-100 (MIM# 107730), or in the 
proprotein convertase subtilisin/kexin type 9 (PCSK9; 
MIM# 607786) gene ( 1 ). 
 At present, more than 1,100 variants of LDLR gene have 
been listed in the LDLR databases underlying a high ge-
netic heterogeneity of LDLR mutations. These are distrib-
uted across the 18 exons, introns, and the promoter region 
of the LDLR gene and include point mutations, insertions, 
deletions, and major rearrangements ( 2 ). 
 Although LDLR defects are primarily identifi ed by ge-
netic methods, it is extremely important to demonstrate a 
defi ciency in the LDLR function of FH suspect patients 
through functional studies. Receptor assays reported so 
far include measurement of radiolabeled-LDL or fl uores-
cently-labeled LDL binding and/or uptake in skin fi broblasts 
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FBS (Lonza) and 10% DMSO in liquid nitrogen until required 
for use. 
 EBV-transformed cell lines were generated by exposing 
PBMCs to free EBV particles, produced by an EBV-infected mar-
moset cell line (B95.8). After EBV infection, transformed PBMCs 
were cultured in an incubator at 37°C in a 5% CO 2 atmosphere 
in Iscove’s Modifi ed Dulbecco’s Medium (IMDM, Sigma-Aldrich) 
supplemented with 20% FBS and 2% Ultraglutamine (Lonza). 
The continuous cell lines bearing the LDLR mutations were also 
analyzed to verify the presence of DNA variations. In order to 
upregulate LDLR, the cells were incubated in a medium contain-
ing a lipoprotein deprived serum (LPDS, Sigma-Aldrich) for 48 h 
before being analyzed. 
 Peripheral blood T-lymphocytes stimulation 
 After two wash steps in FBS, thawed PBMC were counted and 
seeded in a 24-well plate (BD-Falcon) at 1 × 10 6 cells/ml in 
IMDM supplemented with 10% human LPDS to induce LDLR 
upregulation and 2% Ultraglutamine. Stimulation of T-lympho-
cytes was carried out for 48 h at 37°C and 5% CO 2 with three 
different combinations of mitogens:  1 ) 5  g/ml phytohemagglu-
tinin (PHA) (Sigma-Aldrich),  2 ) PHA and 10 ng/ml phorbol 
12-myristate 13-acetate (PMA, Sigma-Aldrich), and  3 ) 1   M ion-
omycin (Sigma-Aldrich) and 10 ng/ml PMA according to Makar 
et al. ( 12 ). 
 LDL uptake assay by fl uorescent-activated cell sorter 
fl ow cytometry 
 Residual LDLR activity was evaluated by measuring the 
binding and uptake of a fl uorescently labeled LDL, namely 
1,19-dioctadecyl-3,3,3 ′ ,3 ′ -tetramethylindocarbocyanine perchlo-
rate-conjugated LDL (DiI-LDL, Invitrogen), in EBV-transformed 
B lymphocytes and mitogen-stimulated T-lymphocytes. Briefl y, 
cells were collected and diluted at 1 × 10 6 cells/ml in DMEM:F12 
(Sigma-Aldrich) without phenol red and LPDS. Two aliquots of 
cells for each sample analyzed were then incubated for 3 h at 
37°C and 5% CO 2 as follows:  a ) with 30 mg/L unlabeled LDL 
(Sigma-Aldrich), to measure background fl uorescence; and  b ) 
with 10 mg/L DiI-LDL to estimate the maximum LDL binding 
and uptake. In preliminary experiments we performed an addi-
tional incubation with 30 mg/L unlabeled LDL plus 10 mg/L 
DiI-LDL (ratio 3:1) to evaluate the displacement of DiI-LDL and 
in this condition, we observed a reduction of cell fl uorescence 
indicating the specifi c binding of DiI-LDL (supplementary  Fig. I ). 
After three washes in with PBS without Ca 2+ and Mg 2+ , fl uores-
cence intensities were measured with a FACSCanto (Becton-
Dickinson) fl ow cytometer according to the manufacturer’s 
instructions. Forward scatter and side scatter gates were estab-
lished to exclude dead cells and cell debris. An example of fl ow 
cytometry gating is shown in supplementary  Fig. II that also shows 
the percentage of CD3 + cells (T-lymphocytes) obtained with the 
ionomycin plus PMA stimulation. For each experiment, 10,000 
events were counted. 
 The results are expressed as the median of fl uorescence and as 
the ratio between the median fl uorescence intensity of cells from 
FH patients and the mean of the median fl uorescence intensity 
of control cells. This ratio represents residual LDLR activity. All 
measurements were performed in duplicate. 
 Statistical analysis 
 The normality of variable distributions was evaluated with Kol-
mogorov-Smirnov test. Continuous variables were indicated as 
mean ± SD. Differences between the continuous variables were 
evaluated with  t -test. A value of  P < 0.05 was considered statisti-
cally signifi cant. Statistical analyses were carried out using the 
( 3, 4 ) or leukocytes ( 5, 6 ). The Epstein-Barr virus (EBV)-
transformed B-lymphocytes show high LDLR levels and al-
low an unlimited supply of cells without being infl uenced 
by the patient’s diet and drug treatment ( 7 ). The main 
problem of these functional assays was the bad separation 
between residual LDLR activity from FH patients and con-
trols. The separation of different leukocyte populations 
obtains more accurate results ( 8 ); the selection of viable 
lymphocytes by stimulation with a mitogen or by fl ow 
cytometry gating improves the discrimination between pa-
tients and controls although it does not allow complete 
discrimination of FH heterozygote patients from healthy 
controls ( 9, 10 ). 
 The aim of this study was to improve the method of 
T-lymphocyte stimulation for LDLR activity evaluation 
through the comparison of different mitogen combina-
tions. We also aimed to compare continuous EBV-trans-
formed-lymphocytes and mitogen stimulated T- lymphocytes 
obtained from peripheral blood samples in order to iden-
tify the best method to detect LDLR activity by fl uores-
cently-labeled LDL. In addition, we characterized both 
novel and known mutations in the LDLR gene. 
 MATERIALS AND METHODS 
 FH patients and control subjects 
 Patients with clinically diagnosed FH were enrolled at the Di-
partimento di Medicina Clinica e Sperimentale, Università degli 
Studi di Napoli Federico II and at the AORN Cardarelli, Napoli. 
The FH diagnosis was based on the criteria established by the 
Società Italiana per lo Studio della Arteriosclerosi for the identi-
fi cation and treatment of dyslipidemias. Twenty-four patients 
bearing new and known mutations were selected for functional 
characterization. As healthy controls, 24 unrelated subjects were 
selected from voluntary donors of the Centro Trasfusionale of 
the AORN Cardarelli, Napoli, on the basis of normal lipid levels 
and absence of LDLR mutations. The supplementary table re-
ports characteristics of FH patients and controls. The study was 
performed according to the current version of the Helsinki Dec-
laration. Informed consent was obtained for each patient. 
 Mutation screening 
 Molecular analysis for the identifi cation of LDLR mutations 
was performed as previously described ( 11 ). Briefl y, the pro-
moter and the 18 exons of the LDLR gene were amplifi ed by PCR 
and directly sequenced. In the case of novel mutations, we veri-
fi ed the absence in 150 chromosomes from normocholester-
olemic individuals of the same ethnic group, the segregation of 
the sequence variant in the relatives available, and the conserva-
tion of substituted amino acid residues across homologous pro-
teins by BLASTP. 
 Mononuclear cell isolation and generation 
of EBV-transformed B-lymphocytes 
 Peripheral blood mononuclear cells (PBMCs) were isolated 
from 9 ml of EDTA blood collected from each subject enrolled in 
this study. The sample was diluted 1 in 2 with PBS without Ca 2+ 
and Mg 2+ pH 7.4, and then layered on Ficoll-Paque (Lymphocyte 
Separation Medium, MP Biomedicals). After centrifugation 
at 1,500 rpm for 30 min at 4°C, mononuclear cells were recov-
ered at interface, washed three times in PBS and stored in 90% 
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87.3%, respectively. As regards LDL-R expression evaluated 
by the uptake of DiI-LDL, in case of PHA stimulation, the 
uptake of DiI-LDL was lower than that observed with PHA 
plus PMA and ionomycin plus PMA (supplementary Fig. I). 
Due to the higher yield of live T-lymphocytes obtained with 
ionomycin plus PMA with respect to PHA plus PMA and 
considering the LDLR upregulation in T-lymphocytes de-
scribed by Makar et al. ( 12 ) using ionomycin plus PMA, we 
selected this method for further experiments. 
 Functional characterization of LDLR activity 
 The median of fl uorescence intensity and the residual 
LDLR activity evaluated in EBV-transformed B-lympho-
cytes and in ionomycin plus PMA stimulated T-lympho-
cytes from healthy subjects with normal lipid profi le and 
no mutations in LDLR are reported in  Table 1 . A repre-
sentative set of data from fl ow cytometry analysis is shown 
in supplementary Fig. III. The residual LDLR activity was 
calculated using the mean of median values of all analyzed 
controls as areference (1,752 for EBV-transformed B-lym-
phocytes and 1,011 for stimulated T-lymphocytes). As for 
controls, this calculation represents a data normalization 
allowing the comparison between the two methods used. 
The minimum and maximum values of residual LDLR ac-
tivity evaluated on EBV-transformed B-lymphocytes from 
controls were 71% and 132%, respectively, whereas the 
minimum and maximum values of residual LDLR activity 
evaluated on stimulated T-lymphocytes were 79% and 
133%, respectively. The median of fl uorescence intensity 
and the residual LDLR activity in EBV-transformed B-lym-
phocytes and in stimulated T-lymphocytes from FH pa-
tients with mutations in LDLR gene are reported in  Table 2 . 
 The residual LDLR activities were statistically different be-
tween control subjects and FH patients analyzed by both 
methodologies ( P < 0.0001 both). Regarding the func-
tional characterization of new mutations, we observed low 
residual LDLR activities consistent with a heterozygous sta-
tus of FH ( Table 2 ). 
 Figure 1  shows a graphical representation of residual 
LDLR activity of each control and FH patient evaluated by 
the two methods. We observed that, using EBV-transformed 
B-lymphocytes, there is an overlap of residual LDLR activi-
ties between controls and patients in the range 71–75%, 
whereas, using stimulated T-lymphocytes, no value in the 
range 65–79% was observed for controls nor for FH pa-
tients. The use of stimulated T-lymphocytes allows a com-
plete discrimination between controls and FH patients. 
 Analysis of ROC curves 
 The ROC curves are constructed using the residual 
LDLR activity evaluated in EBV-transformed B-lympho-
cytes and in stimulated T-lymphocytes as a discriminator 
parameter between FH patients and healthy controls ( Fig. 2 ). 
 The AUC of the methods based on EBV-transformed 
B-lymphocytes and on stimulated T-lymphocytes are 0.984 
[95% confi dence interval (CI) 0.880–1.000] and 1.000 
(95% CI 0.907–1.000), respectively ( P < 0.0001 both). The 
comparison of the AUC of the two methods does not re-
veal any statistically signifi cant difference ( P = 0.41). 
statistical Predictive Analytics Software version 18.0 (SPSS Inc.). 
Analysis of receiver operating characteristic (ROC) curves and 
dot diagrams was performed with MedCalc Version 11.5.1. The 
statistical signifi cance of the area under the ROC curves (AUC) 
was calculated against the null hypothesis AUC = 0.5 as recom-
mended by DeLong et al. ( 13 ). The threshold values were deter-
mined by the farthest point from the bisector of the ROC curve. 
 RESULTS 
 Mutation screening 
 We identifi ed four new mutations absent in 150 chro-
mosomes from normal individuals ( Table 1 ). These altera-
tions are novel missense mutations (c.440C>T; c.974G>A; 
c.1130G>T; c.1739C>T) that result in a single amino acid 
substitution in LDL receptor protein (p.Thr147Ile; 
p.Cys325Tyr; p.Cys377Phe; p.Ser580Phe). The novel mu-
tations cause changes of amino acid residues conserved 
across fourteen species examined during our study. 
 T-lymphocytes mitogen selection 
 In order to select the best way to stimulate T-lympho-
cytes able to express LDLR, we compared three known 
procedures for in vitro growth stimulation of T-cells. The 
fl ow cytometry analysis showed that the amount of viable 
T-lymphocytes in cells treated with  1 ) PHA,  2 ) PHA plus 
PMA, and  3 ) ionomycin plus PMA was 76.4%, 83.8%, and 
 TABLE 1. Medians of fl uorescent intensity and LDLR residual 
activities evaluated on EBV-transformed B-lymphocytes and stimulated 
T-lymphocytes from control subjects. 
Control ID
Median of 
fl uorescent 
intensity 
on EBV-
transformed 
B-lymphocytes
Median of 
fl uorescent 
intensity on 
stimulated 
T-lymphocytes
LDLR residual 
activity on EBV-
transformed 
B-lymphocytes
LDLR residual 
activity on 
stimulated 
T-lymphocytes
Control 1 2,173 1,132 124.0 111.9
Control 2 1,654 1,161 94.4 114.8
Control 3 1,754 1,349 100.1 133.4
Control 4 2,304 931 131.5 92.0
Control 5 1,981 1,106 113.0 109.3
Control 6 2,150 928 122.7 91.7
Control 7 2,103 1,103 120.0 109.0
Control 8 1,524 948 86.9 93.7
Control 9 1,289 869 73.5 85.9
Control 10 2,056 952 117.3 94.1
Control 11 1,924 904 109.8 89.4
Control 12 1,257 799 71.7 79.0
Control 13 1,582 – 90.2 –
Control 14 1,387 – 79.1 –
Control 15 1,238 – 70.6 –
Control 16 1,658 – 94.6 –
Control 17 – 1,048 – 103.6
Control 18 – 963 – 95.2
Control 19 – 905 – 89.5
Control 20 – 1,231 – 121.7
Control 21 – 1,101 – 108.9
Control 22 – 940 – 92.9
Control 23 – 882 – 87.2
Control 24 – 960 – 94.9
Mean ± SD 1,752 ± 355 1,011 ± 138 100.0 ± 20.3 100.0 ± 13.6
CV% 20.3 13.6 20.3 13.6
Missing data are relative to unavailable samples. CV%, coeffi cient 
of variation.
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because in our experimental conditions, it gives the best 
results. In other studies, functional assays were conducted 
on T-lymphocytes using only PHA ( 21, 22 ) although the 
comparison between different mitogens was not per-
formed. For the fi rst time, we compared two cell culture 
techniques useful in detecting residual LDLR activity in 
FH patients: EBV-transformed B-lymphocytes and mitogen 
stimulated T-lymphocytes both treated with fl uorescently-
labeled LDL. In controls, we observed a higher median of 
fl uorescent intensity in EBV-transformed B-lymphocytes 
than in stimulated T-lymphocytes, suggesting the highest 
LDLR expression in the fi rst cell type. The residual LDLR 
activity evaluated on stimulated T-lymphocytes of controls 
shows a more limited range of values, suggesting a minor 
LDLR expression variability. 
 The minimum value of residual LDLR activity in con-
trols is higher for stimulated T-lymphocytes than for EBV-
transformed B-lymphocytes (79% and 71%, respectively) 
suggesting that the T-lymphocytes based method has a bet-
ter capacity to detect functional activity than the other 
one. With ionomycin plus PMA stimulated T-lymphocytes, 
no value was observed in the range 65–79% (discriminat-
ing range) for controls nor for FH patients, whereas using 
EBV-transformed B-lymphocytes, we observed an overlap in 
residual LDLR activities between controls and patients in the 
range 71–75% (absence of a discriminating range). Then, 
using stimulated T-lymphocytes, we obtained a complete dis-
crimination between FH patients and normocholesterolemic 
 By the analysis of ROC curves, the suggested threshold 
of residual LDLR activity for discrimination between con-
trols and patients is 67.7% for EBV-transformed B-lympho-
cytes (86.96% sensitivity and 100% specifi city) and 64.6% 
for stimulated T-lymphocytes (100% sensitivity and 100% 
specifi city). 
 DISCUSSION 
 The functional characterization of LDLR mutations by 
use of EBV-transformed B-lymphocytes provides the ad-
vantages of continuous cell lines that undergo rapid prolif-
eration combined with a long lifespan. These are easily 
reestablished in culture after being frozen and are useful 
in the creation of cell banks for future molecular studies. 
These advantages enable a reliable characterization of 
novel and known mutations in LDLR gene and other ge-
netic disorders ( 20 ). However, EBV-transformed B-lym-
phocytes must be used carefully because of decreased 
genetic stability and possible changes in cellular processes 
induced by viral transformation ( 20 ). The generation of 
EBV-transformed B-lymphocytes is wasteful, time-consum-
ing, and often results tare unproductive depending on the 
quantity of leukocytes isolated from each subject. 
 In order to overcome these problems, we have improved 
an assay to evaluate LDLR activity in peripheral-blood lym-
phocytes using ionomycin plus PMA-induced proliferat-
ing T-lymphocytes. We selected this mitogen combination 
 TABLE 2. Medians of fl uorescent intensity and residual LDLR activities evaluated on EBV-transformed 
B-lymphocytes and stimulated T-lymphocytes from FH patients 
Nucleotide change Effect on protein Reference Status
Median of 
fl uorescent 
intensity on EBV-
transformed 
B-lymphocytes
Median of 
fl uorescent 
intensity on 
stimulated 
T-lymphocytes
LDLR residual 
activity on EBV-
transformed 
B-lymphocytes
LDLR residual 
activity on 
stimulated 
T-lymphocytes
c.116_117
delGCinsAA
p.Cys39X 11 heterozygote 1,113 444 63.5 43.9
c.367T>C and 
c.1478_1479delCT
p.Ser123Pro and 
p.Ser493CysfsX42
11 and 14 compound 
heterozygote
459 – 26.1 –
c.407A>T p.Asp136Val 11 heterozygote 1,097 – 62.6 –
c.407A>T and 
c.1775G>A
p.Asp136Val and 
p.Gly592Glu
11 and 15 compound 
heterozygote
516 220 29.4 21.7
c.424_430
delTCCTGCC
p.Ser142ArgfsX62 11 heterozygote 1,186 647 67.6 64.0
c.440C>T p.Thr147Ile new heterozygote 982 – 56.0 –
c.440C>T p.Thr147Ile new heterozygote 1,241 562 70.8 55.6
c.974G>A p.Cys325Tyr new heterozygote 949 572 54.1 56.6
c.1130G>T p.Cys377Phe new heterozygote 750 – 42.8 –
c.1135T>C p.Cys379Arg 15 heterozygote 1,157 566 66.0 56.0
c.1187-10G>A p.Gly396AspfsX19 16 heterozygote 944 – 53.8 –
c.1187-10G>A p.Gly396AspfsX19 16 heterozygote 1,317 615 75.1 60.8
c.1567G>A p.Val523Met 17 heterozygote 635 607 36.2 60.0
c.1646G>A p.Gly549Asp 18 heterozygote 979 354 55.8 35.0
c.1646G>A p.Gly549Asp 18 heterozygote 831 653 47.4 64.6
c.1646G>A p.Gly549Asp 18 heterozygote 1,149 503 65.5 49.7
c.1739C>T p.Ser580Phe new heterozygote 1,152 646 65.7 63.9
c.1739C>T and 
c.1646G>A
p.Ser580Phe and 
p.Gly549Asp
new and 18 compound 
heterozygote
741 306 42.2 30.2
c.1775G>A p.Gly592Glu 15 heterozygote 1,284 – 73.2 –
c.1775G>A p.Gly592Glu 15 homozygote 682 537 38.9 53.1
c.1846-?_2311+?del p.Asp616LeufsX17 17 heterozygote 338 367 19.2 36.3
c.2312-3C>A p.Ala771_796del 19 heterozygote 724 567 41.3 56.1
c.2312-3C>A p.Ala771_796del 19 heterozygote 763 478 43.5 47.2
c.2312-3C>A p.Ala771_796del 19 heterozygote – 653 – 64.6
Missing data are relative to unavailable samples.
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simple and fast and improves the detection of LDL recep-
tor activity defects, allowing complete discrimination 
between controls and FH patients. Furthermore, the 
evaluation of residual LDLR activity could be helpful not 
only for mutation characterization but also for diagnostic 
purposes.  
 The authors gratefully acknowledge the contribution of the 
Biobank of CEINGE for isolation of peripheral blood mononuclear 
cells and generation of EBV-transformed cell lines. 
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to 64.6% with a 100% sensitivity and a 100% specifi city, 
although the use of a higher threshold in the discriminat-
ing range (65–79%) could improve the diagnostic sensitiv-
ity of the method. 
 To date, many techniques have been used to diagnose 
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point mutations, multiplex ligation-dependent probe am-
plifi cation to identify large rearrangements, and RNA analy-
sis for splicing variants ( 2, 23–25 ). The residual LDLR 
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time-consuming than other described techniques such as 
the use of EBV-transformed B-lymphocytes whose genera-
tion requires to work in class 1 biosafety level laboratories. 
 In conclusion, our method based on the DiI-LDL up-
take in ionomycin plus PMA-stimulated T-lymphocytes is 
 Fig.  1. LDLR activity in controls and FH patients evaluated in 
EBV-transformed B-lymphocytes and stimulated T-lymphocytes. A: 
EBV-transformed B-lymphocytes; B: stimulated T-lymphocytes. 
Data are presented as percentage of LDLR activity. The p-values are 
related to the comparison between controls and FH patients. 
 Fig.  2. Receiver operating characteristic (ROC) curves of LDLR 
activity evaluated in EBV-transformed B-lymphocytes and stimu-
lated T-lymphocytes. A: EBV-transformed B-lymphocytes; B: stimu-
lated T-lymphocytes. The ROC curve is indicated with bold line 
and open circles represent the criterion points. Light line indicate 
the 95% confi dence interval (CI). Dotted line indicate the bisector. 
AUC, area under the curve. 
 at Biblioteche biom
ediche Universita' di Torino, on July 4, 2012
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2011/08/24/jlr.D017772.DC1
Supplemental Material can be found at:
2100 Journal of Lipid Research Volume 52, 2011
  5 .  Schmitz ,  G. ,  T.  Brüning ,  E.  Kovacs , and  S.  Barlage .  1993 . 
 Fluorescence fl ow cytometry of human leukocytes in the detection 
of LDL receptor defects in the differential diagnosis of hypercho-
lesterolemia.  Arterioscler. Thromb.  13 :  1053 – 1065 . 
  6 .  Løhne ,  K. ,  P.  Urdal ,  T. P.  Leren ,  S.  Tonstad , and  L.  Ose .  1995 . 
 Standardization of a fl ow cytometric method for measurement of 
low-density lipoprotein receptor activity on blood mononuclear 
cells.  Cytometry .  20 :  290 – 295 . 
  7 .  Chan ,  P. ,  C.  Jones ,  R.  Lafrenière , and  H. G.  Parsons .  1997 .  Surface 
expression of low density lipoprotein receptor in EBV-transformed 
lymphocytes: characterization and use for studying familial hyperc-
holesterolemia.  Atherosclerosis .  131 :  149 – 160 . 
  8 .  Raungaard ,  B. ,  F.  Heath ,  J. U.  Brorholt-Petersen ,  H. K.  Jensen , and 
 O.  Faergeman .  1999 .  Flow cytometric assessment of LDL receptor 
activity in peripheral blood mononuclear cells compared to gene 
mutation detection in diagnosis of heterozygous familial hypercho-
lesterolemia.  Cytometry .  36 :  52 – 59 . 
  9 .  Tada ,  H. ,  M.  Kawashiri ,  T.  Noguchi ,  M.  Mori ,  M.  Tsuchida ,  M. 
 Takata ,  A.  Nohara ,  A.  Inazu ,  J.  Kobayashi ,  A.  Yachie ,  et al .  2009 .  A 
novel method for determining functional LDL receptor activity in 
familial hypercholesterolemia: application of the CD3/CD28 assay 
in lymphocytes.  Clin. Chim. Acta .  400 :  42 – 47 . 
 10 .  Urdal ,  P. ,  T. P.  Leren ,  S.  Tonstad ,  P. K.  Lund , and  L.  Ose .  1997 . 
 Flow cytometric measurement of low density lipoprotein receptor 
activity validated by DNA analysis in diagnosing heterozygous famil-
ial hypercholesterolemia.  Cytometry .  30 :  264 – 268 . 
 11 .  Romano ,  M. ,  M. D.  Di Taranto ,  M. N.  D’Agostino ,  G.  Marotta , 
 M.  Gentile ,  G.  Abate ,  P.  Mirabelli ,  R.  Di Noto ,  L.  Del Vecchio ,  P. 
 Rubba ,  et al .  2010 .  Identifi cation and functional characterization 
of LDLR mutations in familial hypercholesterolemia patients from 
Southern Italy.  Atherosclerosis .  210 :  493 – 496 . 
 12 .  Makar ,  R. S. ,  P. E.  Lipsky , and  J. A.  Cuthbert .  1994 .  Non-sterol 
regulation of low density lipoprotein receptor gene expression in 
T cells.  J. Lipid Res.  35 :  1888 – 1895 . 
 13 .  DeLong ,  E. R. ,  D. M.  DeLong , and  D. L.  Clarke-Pearson .  1988 . 
 Comparing the areas under two or more correlated receiver oper-
ating characteristic curves: a nonparametric approach.  Biometrics . 
 44 :  837 – 845 . 
 14 .  Cavanaugh ,  J. A. ,  S.  Easteal ,  L. A.  Simons ,  D. W.  Thomas , and  S. W. 
 Serjeantson .  1994 .  FH-Sydney 1 and 2: two novel frameshift muta-
tions in exon 10 of the low-density lipoprotein receptor gene de-
tected by heteroduplex formation.  Hum. Mutat.  4 :  276 – 280 . 
 15 .  Hobbs ,  H. H. ,  M. S.  Brown , and  J. L.  Goldstein .  1992 .  Molecular 
genetics of the LDL receptor gene in familial hypercholester-
olemia.  Hum. Mutat.  1 :  445 – 466 . 
 16 .  Wang ,  J. ,  E.  Huff ,  L.  Janecka , and  R. A.  Hegele .  2001 .  Low density 
lipoprotein receptor (LDLR) gene mutations in Canadian subjects 
with familial hypercholesterolemia, but not of French descent. 
 Hum. Mutat.  18 :  359 . 
 17 .  Hobbs ,  H. H. ,  D. W.  Russell ,  M. S.  Brown , and  J. L.  Goldstein .  1990 . 
 The LDL Receptor locus in familial hypercholesterolemia: mutational 
analysis of a membrane protein.  Annu. Rev. Genet.  24 :  133 – 170 . 
 18 .  Bertolini ,  S. ,  S.  Cassanelli ,  R.  Garuti ,  M.  Ghisellini ,  M. L.  Simone , 
 M.  Rolleri ,  P.  Masturzo , and  S.  Calandra .  1999 .  Analysis of LDL re-
ceptor gene mutations in Italian patients with homozygous familial 
hypercholesterolemia.  Arterioscler. Thromb. Vasc. Biol.  19 :  408 – 418 . 
 19 .  Liguori ,  R. ,  A. M.  Bianco ,  A.  Argiriou ,  P.  Pauciullo ,  A.  Giannino , 
 P.  Rubba , and  V.  De Simone .  2001 .  LDL receptor cDNA sequence 
analysis in familial hypercholesterolemia patients: 5 novel muta-
tions with high prevalence in families originating from southern 
Italy.  Hum. Mutat.  17 :  433 . 
 20 .  Sie ,  L. ,  S.  Loong , and  E. K.  Tan .  2009 .  Utility of lymphoblastoid cell 
lines.  J. Neurosci. Res.  87 :  1953 – 1959 . 
 21 .  Chan ,  P. C. ,  A.  Edwards ,  R.  Lafrenière , and  H. G.  Parsons .  1998 . 
 Improved detection of familial hypercholesterolemia by determin-
ing low density lipoprotein receptor expression in mitogen-induced 
proliferating lymphocytes.  J. Lipid Res.  39 :  2261 – 2270 . 
 22 .  Cuthbert ,  J. A. ,  C. A.  East ,  D. W.  Bilheimer , and  P. E.  Lipsky .  1986 . 
 Detection of familial hypercholesterolemia by assaying functional 
low-density-lipoprotein receptors on lymphocytes.  N. Engl. J. Med. 
 314 :  879 – 883 . 
 23 .  Minhas ,  R. ,  S. E.  Humphries ,  N.  Qureshi , and  H. A.  Neil ;  NICE 
Guideline Development Group .  2009 .  Controversies in familial 
hypercholesterolaemia: recommendations of the NICE Guideline 
Development Group for the identifi cation and management of fa-
milial hypercholesterolaemia.  Heart .  95 :  584 – 587 . 
 24 .  Taylor ,  A. ,  D.  Wang ,  K.  Patel ,  R.  Whittall ,  G.  Wood ,  M.  Farrer ,  R. D. 
 Neely ,  S.  Fairgrieve ,  D.  Nair ,  M.  Barbir ,  et al .  2010 .  Mutation detec-
tion rate and spectrum in familial hypercholesterolaemia patients 
in the UK pilot cascade project.  Clin. Genet.  77 :  572 – 580 . 
 25 .  Holla ,  Ø. L. ,  S.  Nakken ,  M.  Mattingsdal ,  T.  Ranheim ,  K. E.  Berge ,  J. 
C.  Defesche , and  T. P.  Leren .  2009 .  Effects of intronic mutations in 
the LDLR gene on pre-mRNA splicing: comparison of wet-lab and 
bioinformatics analyses.  Mol. Genet. Metab.  96 :  245 – 252 . 
 at Biblioteche biom
ediche Universita' di Torino, on July 4, 2012
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2011/08/24/jlr.D017772.DC1
Supplemental Material can be found at:
